Synthesizing the results of the core component-target-pathway network, PPI network, and cluster analysis, we predicted that the core targets for UR-AP treatment of HT are MAPK1, IL6, AKT1, VEGFA, EGFR, and TP53. This evidence concerns the gene MAPK1 and hematocrit.